|
業務類別
|
-- |
|
業務概覽
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. |
| 公司地址
| 7-11 boulevard Haussmann, Paris, FRA, 75009 |
| 電話號碼
| +33 153830963 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.abivax.com |
| 員工數量
| 69 |
| Mr. Sheldon Sloan |
Chief Medical Officer |
-- |
05/04/2024 |
| Mr. Michael Ferguson |
Chief Commercial Officer |
-- |
05/04/2024 |
| Mr. Didier Scherrer |
Chief Scientific Officer |
-- |
05/04/2024 |
| Mr. Pierre Courteille |
Chief Business Officer |
-- |
05/04/2024 |
| Ms. Ida Hatoum |
Chief People Officer |
-- |
05/04/2024 |
| Mr. Didier Blondel |
Chief Financial Officer and Secretary of the Board |
-- |
05/04/2024 |
| Mr. Marc de Garidel |
Chief Executive Officer and Chairman of the Board |
-- |
05/04/2024 |
|
|
| Mr. Troy A. Ignelzi |
Independent Director |
05/04/2024 |
| Dr. June Lee, M.D. |
Independent Director |
05/04/2024 |
| Dr. Carol L. Brosgart, M.D. |
Independent Director |
05/04/2024 |
| Ms. Camilla Soenderby |
Independent Director |
05/04/2024 |
| Dr. Philippe Pouletty |
Director |
05/04/2024 |
| Mr. Marc de Garidel |
Chief Executive Officer and Chairman of the Board |
05/04/2024 |
| Ms. Corinna zur Bonsen-Thomas |
Independent Director |
05/04/2024 |
| Mr. Kinam Hong |
Independent Director |
05/04/2024 |
|
|
|
|
